Chapter 8 Archives • Children's Health Defense

1

Celia Farber, “Out of control: AIDS and the corruption of medical science,” Harper’s Magazine (Mar. 2006).

2

Interview with Robert F. Kennedy Jr., February 2021.

3

John Solomon, “U.S. knew of AIDS drug concerns,” Associated Press (Dec. 14, 2004).

4

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 179.

5

Centre for Research on Multinational Corporations (SOMO), “SOMO briefing paper on ethics in clinical trials #1: Examples of unethical trials,” (Feb. 2008).

6

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 188.

7

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 17.

8

“Serious Adverse Events Attributed to Nevirapine Regimens for Postexposure Prophylaxis After HIV Exposures—Worldwide, 1997–2000,” Morbidity and Mortality Weekly Report (Jan. 5, 2001).

9

Brooks Jackson, Laura A. Guay, et al., “Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial,” The Lancet (Sep. 4, 1999).

10

Brooks Jackson, Laura A. Guay, et al., “Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial,” The Lancet (Sep. 4, 1999).

11

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 114.

12

Brooks Jackson, Laura A. Guay, et al., “Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial,” The Lancet (Sep. 4, 1999).

13

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 179.

14

Westat Division of AIDS Clinical Research Operations and Monitoring Center, Site Visit Report, Pre-Inspection Audit (Mar. 8, 2002).

15

Westat Division of AIDS Clinical Research Operations and Monitoring Center, Site Visit Report, Pre-Inspection Audit (Mar. 8, 2002).

16

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 184.

17

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 184.

18

John Solomon, “NIH was warned in ‘02 on AIDS drug for Africa,” Associated Press (Dec. 14, 2004).

19

John Solomon, “NIH was warned in ‘02 on AIDS drug for Africa,” Associated Press (Dec. 14, 2004).

20

John Solomon, “NIH was warned in ‘02 on AIDS drug for Africa,” Associated Press (Dec. 14, 2004).

21

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008),186.

22

Westat Division of AIDS Clinical Research Operations and Monitoring Center, Site Visit Report, Pre-Inspection Audit,(Mar. 8, 2002).

23

Celia Farber, “Out of control: AIDS and the corruption of medical science,” Harper’s Magazine (Mar. 2006).

24

Anthony Brink, The Trouble with Nevirapine (Open Books, 2008), 179.

25

Michael Carter, “Nevirapine: South African govt tries new ploy to avoid providing HIV drug to mothers,” NAM AIDSMAP (Mar. 28, 2002).

26

Michael Carter, “Nevirapine: South African govt tries new ploy to avoid providing HIV drug to mothers,” NAM AIDSMAP (Mar 28, 2002).

27

E-drug, “Nevirapine /MTCT indication withdrawn in USA,” E-drug (Mar. 25, 2002).

28

The National Academies, Review of the HIVNET 012 Perinatal HIV Prevention Study (National Academies Press, 2005).

29

“NIH AIDS Research Chief Rewrote Safety Report-AP,” AHRP (Oct. 26, 2006).

30

Betsy Smith M.D., “The HIVNET 012 Safety Review Panel: Primary Objectives, Approach, Findings and Summary to Date,” UN Redacted Report (Jan. 24, 2003).